Moreover, we revealed that the combination of USP7 enzymatic inhibitor and afatinib caused a more profound inhibition of tumor progression in vitro and in vivo, partly by suppressing the USP7-HIF2α regulatory axis. Here, EPAS1 is linked to neoplasm.